365Disease burden of mumps in Japan: descriptive epidemiology based on the health insurance reimbursement database

Background In Japan, mumps vaccination coverage is low, since it is a voluntary vaccination. In this situation, the number of mumps cases as reported by pediatric sentinel hospitals suggests the occurrence of periodical mumps outbreaks. Methods To examine the annual incidences of mumps and mumps-related complications, we analyzed data from the health insurance reimbursement database for subscribers aged 0-64 years between 2005 and 2017. Cases with mumps and mumps-related complications including meningitis, orchitis, deafness, were extracted according to ICD-10 codes entered into the disease section for health insurance reimbursement. Results During the 13 year period, 68,307 of 5,209,660 subjects were reimbursed for mumps, with an incidence of 325 per 100,000 person-years (95% confidence interval (CI): 323-328). Among the 68,307 mumps cases, 787 were reimbursed for mumps-related complications, with an incidence of 11.5 per 1,000 mumps cases (95% CI: 10.7-12.4). Incidence of mumps-related complications (per 1,000 mumps cases) was highest for orchitis (6.6), followed by meningitis (5.8), deafness (1.3), pancreatitis (0.5), and encephalitis (0.3). Mumps incidence was highest among children aged 0-5 years, while incidence of mumps-related complications was highest among adults aged 26-35 years. Conclusions In Japan, the disease burden of mumps remains high among adults, as well as children. Key messages To reduce the disease burden of mumps among all ages in Japan, immunization in childhood is required. A national immunization program for children would result in high vaccination coverage and lower disease burden.

The long-term effects of the biolicit procedure for original and biosimilar GCSF and EPO products in Hungary

Aim: We aimed to analyse the long-term effects of the biosimilar bids of NEAK regarding GCSF and EPO drugs. Data and Methods: Our analysis is based on the data derived from the nationwide pharmaceutical database of NEAK. The treatment days and reimbursement figures of 12 months periods has been compared, from 01.07.2011-30.06.2014. and 01.07.2017.-30.06.2019. Results: In the 12 months preceding the price competition bid of biosimilar products 13974 patients received G-CSF, 7.49 billion HUF health insurance reimbursement has been paid, 5 years later the turnover of the product increased (314760, 340100 DOT value), whereas the reimbursement decreased (2.03 billion HUF, 1.95 billion HUF respectively). 12 months before the biosimial price competition, 4167 patients were treated with erythropoietin, resulting in 2.33 billion HUF of reimbursements, in the last 2 years the turnover increased (48727, 50813 DOT value respectively) with decreased reimbursement (1.004 billion HUF, 1.002 billion HUF respectively). Conclusions: The long-range analyses price competition bid of biosimilar products revealed that in case of products the health insurance reimbursement decreased despite the elevated turnover in a longer period as well. During the years following the start of the price competition bid the switch from original products to biosimilars could be observed.